Products Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Phase 2 Completed ⚡ Active Diffuse Large Cell Lymphoma
Diffuse Large Cell Lymphoma
Apr 1, 2003 → Nov 1, 2012
About Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) is a phase 2 stage product being developed by Eli Lilly for Diffuse Large Cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00169195. Target conditions include Diffuse Large Cell Lymphoma.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00169195 Phase 2 Completed Apr 1, 2003 Nov 1, 2012 Diffuse Large Cell Lymphoma
Product Company Stage Hype Score IVA337 + Placebo Inventiva Phase 2 rituximab Celltrion Phase 1 YM155 Astellas Pharma Phase 2 enzastaurin + gemcitabine + rituximab + oxaliplatin Eli Lilly Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Johnson & Johnson Phase 2 VELCADE + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Johnson & Johnson Phase 2 Epcoritamab + Rituximab + Lenalidomide + Oxaliplatin + Gemcitabine AbbVie Phase 3 ABBV-525 AbbVie Phase 1 rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab and lenalidomide + rituximab and bendamustine + rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin + gemcitabine and oxaliplatin + Epcoritamab + rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone + Lenalidomide + rituximab, ifosfamide, carboplatin, and etoposide phosphate + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Epcoritamab + Rituximab and Lenalidomide + Epcoritamab AbbVie Phase 1/2 Copanlisib + Venetoclax AbbVie Phase 1/2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 Epcoritamab + Lenalidomide AbbVie Phase 2 Venetoclax + Selinexor AbbVie Phase 1 Epcoritamab AbbVie Phase 1 Loncastuximab Tesirine and Epcoritamab AbbVie Phase 2 Epcoritamab + Investigator's Choice Chemotherapy AbbVie Phase 3 bendamustine + navitoclax + rituximab AbbVie Phase 2 Epcoritamab AbbVie Phase 2 Epcoritamab (monotherapy) + Epcoritamab + Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone + Gemcitabine and oxaliplatin + Epcoritamab (maintenance) + Rituximab and lenalidomide AbbVie Phase 1/2 Epcoritamab + Ibrutinib AbbVie Phase 1/2
Other Products from Eli Lilly